Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2025 Nov;108(1_suppl):S118-S131.
doi: 10.1177/13872877251343296. Epub 2025 May 25.

Speech-based digital cognitive assessments for detection of mild cognitive impairment: Validation against paper-based neurocognitive assessment scores

Affiliations

Speech-based digital cognitive assessments for detection of mild cognitive impairment: Validation against paper-based neurocognitive assessment scores

Zampeta-Sofia Alexopoulou et al. J Alzheimers Dis. 2025 Nov.

Abstract

BackgroundCognitive decline in Alzheimer's disease (AD) often includes speech impairments, where subtle changes may precede clinical dementia onset. As clinical trials focus on early identification of patients for disease-modifying treatments, digital speech-based assessments for scalable screening have become crucial.ObjectiveThis study aimed to validate a remote, speech-based digital cognitive assessment for mild cognitive impairment (MCI) detection through the comparison with gold-standard paper-based neurocognitive assessments.MethodsWithin the PROSPECT-AD project, speech and clinical data were obtained from the German DELCODE and DESCRIBE cohorts, including 21 healthy controls (HC), 110 participants with subjective cognitive decline (SCD), and 59 with MCI. Spearman rank and partial correlations were computed between speech-based scores and clinical measures. Kruskal-Wallis tests assessed group differences. We trained machine learning models to classify diagnostic groups comparing classification accuracies between gold-standard assessment scores and a speech-based digital cognitive assessment composite score (SB-C).ResultsGlobal cognition, as measured by SB-C, significantly differed between diagnostic groups (H(2) = 30.93, p < 0.001). Speech-based scores were significantly correlated with global anchor scores (MMSE, CDR, PACC5). Speech-based composites for memory, executive function and processing speed were also correlated with respective domain-specific paper-based assessments. In logistic regression classification, the model combining SB-C and neuropsychological tests at baseline achieved a high discriminatory power in differentiating HC/SCD from MCI patients (Area Under the Curve = 0.86).ConclusionsOur findings support speech-based cognitive assessments as a promising avenue towards remote MCI screening, with implications for scalable screening in clinical trials and healthcare.

Keywords: Alzheimer's disease; dementia; digital cognitive assessment; mild cognitive impairment; speech analysis; speech-based digital cognitive assessment; speech-based markers.

PubMed Disclaimer

Conflict of interest statement

Declaration of conflicting interestsThe authors declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Zampeta-Sofia Alexopoulou has nothing to disclose. Alexandra König, Johannes Tröger, Nicklas Linz and Elisa Mallick are employed by the company ki:elements, which developed the application for the automatic phone assessment and calculated the speech-based digital cognitive assessment scores. Johannes Tröger and Nicklas Linz own shares in the ki:elements company. Alexandra König is an Editorial Member of the special issue of this journal but was not involved in the peer-review process of this article nor had access to any information regarding its peer-review. Stefanie Köler has received funding from the Alzheimer Drug Discovery Foundation and the Lilly Deutschland GmbH as well as lecture fees from Eisai. Eike Spruth has nothing to disclose. Klaus Fliessbach has nothing to disclose. Claudia Bartels received funding from the German Alzheimer Association and lecture fees from Lilly, Roche Pharma and Eisai. Ayda Rostamzadeh has nothing to disclose. Wenzel Glanz has nothing to disclose. Enise I. Incesoy has nothing to disclose. Michaela Butryn has nothing to disclose. Ingo Kilimann has nothing to disclose. Mathias Munk has nothing to disclose. Sebastian Sodenkam has nothing to disclose. Antje Osterrath has nothing to disclose. Anna Esser has nothing to disclose. Sandra Roeske has nothing to disclose. Ingo Frommann has nothing to disclose. Melina Stark has nothing to disclose. Luca Kleineidam has nothing to disclose. Annika Spottke has nothing to disclose. Josef Priller has nothing to disclose. Anja Schneider has nothing to disclose. Jens Wiltfang has received funding from the BMBF (German Federal Ministry of Education and Research), consulting fees from Immunogenetics, Noselab, Roboscreen and lecture fees from Beijing Yibai Science and Technology Ltd, Gloryren, Janssen Cilag, Pfizer, Med Update GmbH, Roche Pharma, Lilly. Jens Wiltfang participated on a Data Safety Monitoring Board or Advisory Board of Biogen, Abbott, Boehringer Ingelheim, Lilly, MSD (Merck Sharp and Dohme) Sharp & Dohme, Roche. Frank Jessen has nothing to disclose. Emrah Düzel has nothing to disclose. Bjoern Falkenburger has received funding from the Deutsche Forschungsgemeinschaft. Michael Wagner has nothing to disclose. Christoph Laske has nothing to disclose. Valeria Manera has nothing to disclose. Stefan Teipel participated in scientific advisory boards of Roche Pharma AG, Biogen, Lilly, and Eisai, and received lecture fees from Lilly and Eisai. Stefan Teipel is an Editorial Member of the supplemental issue of this journal but was not involved in the peer-review process of this article nor had access to any information regarding its peer-review.

Figures

Figure 1.
Figure 1.
Overview of the design of the DELCODE and DESCRIBE cohorts and the PROSPECT-AD study.
Figure 2.
Figure 2.
Overview of the structure of the speech-based digital cognitive assessment composite score SB-C and its domain-specific composite scores. Adapted from Tröger et al..
Figure 3.
Figure 3.
(a) Group differences in the SB-C global cognition score between diagnostic groups. (b) Group differences in the SB-C global cognition score according to global CDR scores.
Figure 4.
Figure 4.
Correlations between the SB-C global cognition score and (a) MMSE total score, (b). CDR SoB score, and (c) PACC5 total score. The red line indicates the fitted smoothed regression line and the shaded area represents its confidence intervals.
Figure 5.
Figure 5.
Receiver operator curves for differentiating HC/SCD and MCI patients. The MMSE total score at T0 is displayed in a yellow line. The ADAS-Cog 13 Sum score at T0 is displayed in a purple line. The SB-C global cognition score at M0 is displayed in a green line. The aggregated SB-C global cognition score of M0, M3 and M6 is displayed in a pink line. The model combining MMSE and ADAS-Cog 13 Sum score at T0 and the SB-C global cognition score at M0 is displayed in a red line. ROC-AUC: Receiver Operator Characteristic-Area Under the Curve; MMSE: Mini-Mental State Examination; ADAS-Cog 13 Sum: Alzheimer's Disease Assessment Scale 13-item Cognitive Subscale Sum score. MCI: mild cognitive impairment; SCD: subjective cognitive decline.

References

    1. Wimo A, Seeher K, Cataldi R, et al. The worldwide costs of dementia in 2019. Alzheimers Dement 2023; 19: 2865–2873. - PMC - PubMed
    1. Alzheimer Europe. European Dementia Monitor - Comparing and benchmarking national dementia policies and strategies. Luxembourg: Alzheimer Europe, ISBN 978-2-919811-12-0, https://www.alzheimer-europe.org/resources/publications/european-dementi... (2023, accessed 13 December 2024).
    1. König A, Linz N, Baykara E, et al. Screening over speech in unselected populations for clinical trials in AD (PROSPECT-AD): study design and protocol. J Prev Alzheimers Dis 2023; 10: 314–321. - PMC - PubMed
    1. Saunders S, Haider F, Ritchie CW, et al. Longitudinal observational cohort study: speech for intelligent cognition change tracking and DEtection of Alzheimer’s Disease (SIDE-AD). BMJ Open 2024; 14: e082388. - PMC - PubMed
    1. Cummings J, Zhou Y, Lee G, et al. Alzheimer’s disease drug development pipeline: 2023. Alzheimers Dement (N Y) 2023; 9: e12385. - PMC - PubMed

Publication types

LinkOut - more resources